Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression

This study evaluated the effectiveness of plasma-based assays detecting BRAF and NRAS mutations in circulating tumor DNA (ctDNA) for monitoring metastatic melanoma. Involving patients with unresectable stage IIIC/IV melanoma undergoing BRAF inhibitor therapy or immune checkpoint blockade, ctDNA levels were measured using droplet digital PCR. The assays demonstrated higher sensitivity